Effects of prior administration of amodiaquine on the disposition of halofantrine in healthy volunteers

Therapeutic Drug Monitoring

Volumn 29, Issue 2, 2007, Pages 203-206

  Omoruyi, Sharon I ^a   Onyeji, Cyprian O ^a   Daniyan, Michael O ^a  

^a OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

Author keywords

Amodiaquine; Halofantrine; Interaction; Pharmacokinetics; Prior administration

Indexed keywords

AMODIAQUINE; DEBUTYLHALOFANTRINE; HALOFANTRINE;

ADULT; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CARDIOTOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DISPOSITION; ELECTROGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VOLUNTEER;

ADULT; AMODIAQUINE; ANTIMALARIALS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; PHENANTHRENES;

EID: 34248180608     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31803d39f7     Document Type: Article

References (21)

1. Wirima J, Khoromana C, Molyneux MC. Clinical trials with halofantrine hydrochloride in Malawi. Lancet. 1988;2:50-252.
2. Karbwang J,Ward SA, Milton KA, et al. Pharmacokinetics of halofantrine in healthy Thai volunteers. Br J Clin Pharmacol. 1991;32:639-640.
3. Ngouesse B, Basco LK, Ringwald P, et al. Cardiac effect of amodiaquine and sulphadoxine-pyrimethamine in malaria-infected Africa children. Am J Trop Med Hyg. 2001;65:711-716.
4. World Health Organization. The use of antimalarial drugs. Report of a WHO informal consultation. WHO document WHO/CDS/RBM/2001. 33. Geneva: World Health Organization; 2001:47-50.
5. Wensdorfer WH, Noedi H. Molecular markers for drug resistance in malaria use in treatment, diagnosis and epidemiology. Curr Opin Infect Dis. 2003;16:553-558.
6. Nosten F, Ter Kuile FA, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet. 1993;341:1054-1056.
7. Baune B, Furlan V, Taburet AM, et al. Effects of selected antimalarial drugs and inhibitors of cytochrome P-450 3A4 on halofantrine metabolism by human liver microsomes. Drug Metab Dispos. 1999;27:565-568.
8. Bapiro T, Egnell A, Hasler J, et al. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450's. Drug Metab Dispos. 2001;29:30-35.
9. Halliday RC, Jones BC, Smith DA, et al. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human microsomes and heterologous enzyme expression systems. Br J Clin Pharmacol. 1995;40:369-378.
10. Ong C, Coulter S, Birkett D, et al. The xenobiotic inhibitor profile of cytochrome P450 2C8. Br J Clin Pharmacol. 2000;50:573-580.
11. Traebert M, Dumotier B. Antimalarial drugs: QT prolongation and cardiac arrhythmias. Exp Opin Drug Saf. 2000;4:421-431.
12. Karbwang J, Na-Bangchang K, Bunnag D, et al. Cardiac effect of halofantrine. Lancet. 1993;342:501.
13. Bassi PU, Onyeji CO, Ukponmwan OE. Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. Br J Clin Pharmacol. 2004;58:52-55.
14. Gilbaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Dekker; 1982.
15. Giao PT, de Vries PJ. Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinet. 2001;40:343-373.
16. Milton KA, Edwards G, Wards SA, et al. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol. 1989;28:71-77.
17. Aideloje SO, Onyeji CO, Ugwu NC. Altered pharmacokinetics of halofantrine by an antacid magnesium carbonate. Eur J Pharm Biopharm. 1998;46:299-303.
18. Karbwang J, Na Bangchang K. Clinical pharmacokinetics of halofantrine. Clin Pharmacokinet. 1994;27:104-119.
19. Lefevre G, Carpenter P, Souppart C, et al. Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects. J Clin Pharmacol. 2002;42:1147-1158.
20. Hombhanje FW, Hwaihwanje I, Tsukahara T, et al. The disposition of oral amodiaquine in Papua New Guniea children with falciparum malaria. Br J Clin Pharmacol. 2004;59:298-301.
21. Winstanley PA, Simoooya O, KofiEkue JM, et al. The disposition of amodiaquine in Zambians and Nigerians with malaria. Br J Clin Pharmacol. 1990;29:695-701.